Hudson Bay Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Hudson Bay Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$613K	Sell	71,059 -17,494	-20%	-$146K	﹤0.01%	951
2025 Q4	$832K	Buy	+88,553	New	+$657K	﹤0.01%	818
2024 Q4	–	Sell	-52,035	Closed	-$254K	–	1152
2024 Q3	$254K	Buy	+52,035	New	+$401K	﹤0.01%	745
2024 Q2	–	Sell	-50,000	Closed	-$1.24M	–	971
2024 Q1	$1.24M	Buy	+50,000	New	+$1.4M	0.01%	524

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Hudson Bay Capital Management's KYTX Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Kyverna Therapeutics (KYTX) stake by 20% in Q1 2026, selling an estimated $146K and leaving 71,059 shares worth $613K. The position accounts for ﹤0.01% of the portfolio, ranked #951.

Hudson Bay Capital Management first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $1.24M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Hudson Bay Capital Management held 71,059 shares of Kyverna Therapeutics worth $613K as of Q1 2026.
Hudson Bay Capital Management sold 17,494 Kyverna Therapeutics shares in Q1 2026, an estimated $146K.
Kyverna Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #951 holding.
Hudson Bay Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
Hudson Bay Capital Management's Kyverna Therapeutics position peaked at $1.24M in Q1 2024.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.